Please login to the form below

Not currently logged in
Email:
Password:

Encysive launches Thelin for hypertension in Spain

US-based Encysive Pharmaceuticals has launched Thelin (sitaxentan) 100 mg tablets in Spain for the treatment of pulmonary arterial hypertension (PAH).

US-based Encysive Pharmaceuticals has launched Thelin (sitaxentan) 100 mg tablets in Spain for the treatment of pulmonary arterial hypertension (PAH).

Encysive won EU marketing authorisation for the product from the EU Commission in August 2006.

Thelin is the first marketed selective endothelin A receptor antagonist, and the first once-daily oral treatment available for patients with PAH. Encysive will sell the product through its Spanish marketing partner, Praxis Pharmaceutical.

Thelin is indicated for improving exercise capacity in PAH patients classified as World Health Organisation (WHO) functional class III. Efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease (CTD).

Encysive will successively launch Thelin in all 27 member states of the EU, as local government approval for reimbursement is obtained, says the firm.

George Cole, Encysive's CEO, said: "Through our marketing partnership with Praxis, we are able to immediately begin selling THELIN in Spain without the need to invest in a dedicated sales and marketing infrastructure."

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics